18F-FDG PET/CT-related metabolic parameters and their value in early prediction of chemotherapy response in a VX2 tumor model

Nuclear Medicine and Biology

Volumn 37, Issue 3, 2010, Pages 327-333

  Song, Shao li ^a,b   Deng, Chuang ^c   Wen, Ling feng ^d,e   Liu, Jian jun ^a,b   Wang, Hui ^a,b   Feng, David ^e   Wong, Ching yee Oliver ^f   Huang, Gang ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c STATE GRID CORPORATION OF CHINA   (China)

^d ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

^f WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

18F FDG PET CT; Chemotherapy; Cisplatin; FDG kinetic modeling; VX2 tumors

Indexed keywords

CISPLATIN; FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER 1; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG METABOLISM; DRUG MONITORING; DRUG SENSITIVITY; DRUG UPTAKE; EXPERIMENTAL RABBIT; MALE; NON INVASIVE PROCEDURE; NONHUMAN; NUCLEOTIDE SEQUENCE; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; PROTEIN EXPRESSION; SINGLE DRUG DOSE; TREATMENT RESPONSE; TUMOR VOLUME; ANIMAL; BIOLOGICAL MODEL; COMPUTER ASSISTED DIAGNOSIS; COMPUTER SIMULATION; HUMAN; IMAGE ENHANCEMENT; IMAGE SUBTRACTION; LIVER TUMOR; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; RABBIT; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; CISPLATIN; COMPUTER SIMULATION; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; LIVER NEOPLASMS, EXPERIMENTAL; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; POSITRON-EMISSION TOMOGRAPHY; RABBITS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SUBTRACTION TECHNIQUE; TISSUE DISTRIBUTION; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 77950298014     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2009.12.002     Document Type: Article

References (31)

1. Dalton W.S., Friend S.H. Cancer biomarkers-an invitation to the table. Science 2006, 312(5777):1165-1168.
2. Weissleder R. Molecular imaging in cancer. Science 2006, 312(5777):1168-1171.
3. Weber W.A. Use of PET for monitoring cancer therapy and for predicting outcome. J Nucl Med 2005, 46(6):983-985.
4. Yap J.T., Carney J.P., Hall N.C., Townsend D.W. Image-guided cancer therapy using PET/CT. Cancer J (Sudbury, Mass) 2004, 10(4):221-233.
5. 18F]fluorodeoxyglucose. J Clin Oncol 2009, 27(4):535-541.
6. 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. J Clin Oncol 2009, 27(3):439-445.
7. 18F-FDG uptake in patients with untreated extranodal natural killer/T-cell lymphomas of the head and neck. J Nucl Med 2008, 49(11):1783-1789.
8. Fischman A.J., Alpert N.M. FDG-PET in oncology: there's more to it than looking at pictures. J Nucl Med 1993, 34(1):6-11.
9. Evilevitch V., Weber W.A., Tap W.D., Allen-Auerbach M., Chow K., Nelson S.D., et al. Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas. Clin Cancer Res 2008, 14(3):715-720.
10. 18F-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin's lymphoma-comparison with CT. Leuk Lymphoma 2000, 39(5-6):543-553.
11. 18F-FDG uptake within minutes after chemotherapy in a rabbit VX2 tumor model. J Nucl Med 2008, 49(2):303-309.
12. Römer W., Hanauske A.R., Ziegler S., Thödtmann R., Weber W., Fuchs C., et al. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood 1998, 91(12):4464-4471.
13. 18F-FDG studies in patients with primary and recurrent soft-tissue sarcomas: impact on diagnosis and correlation with grading. J Nucl Med 2001, 42(5):713-720.
14. Dimitrakopoulou-Strauss A., Hoffmann M., Bergner R., Uppenkamp M., Eisenhut M., Pan L., et al. Prediction of short-term survival in patients with advanced non-small cell lung cancer following chemotherapy based on 2-deoxy-2-[F-18]fluoro-d-glucose-positron emission tomography: a feasibility study. Mol Imaging Biol 2007, 9(5):308-317.
15. Liu X.F., Ren L.R., Su G.Y., Liu Y.Q., Gu B., Dong J.H. Establishment and characterization of a rabbit tumor cell line VX2. Zhonghua Bing Li Xue Za Zhi 2005, 34:661-663.
16. Shiozaki T., Sadato N., Senda M., Ishii K., Tsuchida T., Yonekura Y., et al. Noninvasive estimation of FDG input function for quantification of cerebral metabolic rate of glucose: optimization and multicenter evaluation. J Nucl Med 2000, 41(10):1612-1618.
17. Tsuchida T., Sadato N., Yonekura Y., Nakamura S., Takahashi N., Sugimoto K., et al. Noninvasive measurement of cerebral metabolic rate of glucose using standardized input function. J Nucl Med 1999, 40(9):1441-1445.
18. Nishiyama Y., Yamamoto Y., Monden T., Sasakawa Y., Kawai N., Satoh K., et al. Diagnostic value of kinetic analysis using dynamic FDG PET in immunocompetent patients with primary CNS lymphoma. Eur J Nucl Med Mol Imaging 2007, 34(1):78-86.
19. 18F] fluorodeoxyglucose positron emission tomography images. Phys Med Biol 2007, 52(23):7055-7071.
20. 18F-FDG PET studies. J Nucl Med 2006, 47(6):945-949.
21. Fang Y.H., Kao T., Liu R.S., Wu L.C. Estimating the input function non-invasively for FDG-PET quantification with multiple linear regression analysis: simulation and verification with in vivo data. Eur J Nucl Med Mol Imaging 2004, 31:692-702.
22. 82Rb dynamic PET imaging. Eur J Nucl Med Mol Imaging 2007, 34(11):1765-1774.
23. Melstrom L.G., Salabat M.R., Ding X.Z., Milam B.M., Strouch M., Pelling J.C., et al. Apigenin inhibits the GLUT-1 glucose transporter and the phosphoinositide 3-kinase/Akt pathway in human pancreatic cancer cells. Pancreas 2008, 37(4):426-431.
24. Yasuda M., Miyazawa M., Fujita M., Kajiwara H., Iida T., Hirasawa T., et al. Expression of hypoxia inducible factor-1alpha (HIF-1alpha) and glucose transporter-1 (GLUT-1) in ovarian adenocarcinomas: difference in hypoxic status depending on histological character. Oncol Rep 2008, 19(1):111-116.
25. Li J., Yang S.J., Zhao X.L., Zhang Y.Q., Li K.N., Cui J.H., et al. Significant increase of glucose transport activity in breast cancer. Zhonghua Bingli Xue Za Zhi 2008, 37(2):103-108.
26. 3H-FDG uptake and key gene expression in breast cancer cells undergoing chemotherapy. J Nucl Med 2006, 47(4):603-608.
27. 18F-fluoro-2-deoxy-d-glucose rate constants in the anesthetized baboon brain with dynamic positron tomography. J Neurosci Methods 1993, 50(3):263-272.
28. Wu H.M., Huang S.C., Choi Y., Hoh C.K., Hawkins R.A. A modeling method to improve quantitation of fluorodeoxyglucose uptake in heterogeneous tumor tissue. J Nucl Med 1995, 36(2):297-306.
29. Green L.A., Gambhir S.S., Srinivasan A., Banerjee P.K., Hoh C.K., Cherry S.R., et al. Noninvasive methods for quantitating blood time-activity curves from mouse PET images obtained with fluorine-18-fluorodeoxyglucose. J Nucl Med 1998, 39(4):729-734.
30. Dimitrakopoulou-Strauss A., Strauss L. Quantitative studies using positron emission tomography (PET) for the diagnosis and therapy planning of oncological patients. Hell J Nucl Med 2006, 9(1):10-21.
31. Negoita C. Global Kinetic Imaging Using Dynamic Positron Emission Tomography Data 2003, Arizona State University, Phoneix, USA.